Literature DB >> 20564356

Rapid protein production using CHO stable transfection pools.

Jianxin Ye1, Krista Alvin, Haythem Latif, Amy Hsu, Vanessa Parikh, Travis Whitmer, Melanie Tellers, M Celina de la Cruz Edmonds, Jeffrey Ly, Peter Salmon, Julia F Markusen.   

Abstract

During early preclinical development of therapeutic proteins, representative materials are often required for process development, such as for pharmacokinetic/pharmacodynamic studies in animals, formulation design, and analytical assay development. To rapidly generate large amounts of representative materials, transient transfection is commonly used. Because of the typical low yields with transient transfection, especially in CHO cells, here we describe an alternative strategy using stable transfection pool technology. Using stable transfection pools, gram quantities of monoclonal antibody (Mab) can be generated within 2 months post-transfection. Expression levels for monoclonal antibodies can be achieved ranging from 100 mg/L to over 1000 mg/L. This methodology was successfully scaled up to a 200 L scale using disposable bioreactor technology for ease of rapid implementation. When fluorescence-activated cell sorting was implemented to enrich the transfection pools for high producers, the productivity could be improved by about three-fold. We also found that an optimal production time window exists to achieve the highest yield because the transfection pools were not stable and productivity generally decreased over length in culture. The introduction of Universal chromatin-opening elements elements into the expression vectors led to significant productivity improvement. The glycan distribution of the Mab product generated from the stable transfection pools was comparable to that from the clonal stable cell lines.
© 2010 American Institute of Chemical Engineers

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20564356     DOI: 10.1002/btpr.469

Source DB:  PubMed          Journal:  Biotechnol Prog        ISSN: 1520-6033


  15 in total

1.  Non-viral adeno-associated virus-based platform for stable expression of antibody combination therapeutics.

Authors:  Gwendolyn M Wilmes; Kimberly L Carey; Stuart W Hicks; Hugh H Russell; Jesse A Stevenson; Paulina Kocjan; Stephen R Lutz; Rachel S Quesenberry; Sergey V Shulga-Morskoy; Megan E Lewis; Ethan Clark; Violetta Medik; Anthony B Cooper; Elizabeth E Reczek
Journal:  MAbs       Date:  2014-04-23       Impact factor: 5.857

2.  An efficient route to bispecific antibody production using single-reactor mammalian co-culture.

Authors:  Whitney Shatz; Domingos Ng; George Dutina; Athena W Wong; Diana Ronai Dunshee; Junichiro Sonoda; Amy Shen; Justin M Scheer
Journal:  MAbs       Date:  2016 Nov/Dec       Impact factor: 5.857

3.  Early integration of Design of Experiment (DOE) and multivariate statistics identifies feeding regimens suitable for CHO cell line development and screening.

Authors:  Alessandro Mora; Bernard Nabiswa; Yuanyuan Duan; Sheng Zhang; Gerald Carson; Seongkyu Yoon
Journal:  Cytotechnology       Date:  2019-11-09       Impact factor: 2.058

Review 4.  Recent advances in mammalian protein production.

Authors:  Ashok D Bandaranayake; Steven C Almo
Journal:  FEBS Lett       Date:  2013-12-06       Impact factor: 4.124

5.  Effects of ubiquitous chromatin opening element (UCOE) on recombinant anti-TNFα antibody production and expression stability in CHO-DG44 cells.

Authors:  Chinh Chung Doan; Thanh Long Le; Nguyen Quynh Chi Ho; Nghia Son Hoang
Journal:  Cytotechnology       Date:  2021-10-23       Impact factor: 2.058

6.  Transient expression of human antibodies in mammalian cells.

Authors:  Rodrigo Vazquez-Lombardi; Damien Nevoltris; Ansha Luthra; Peter Schofield; Carsten Zimmermann; Daniel Christ
Journal:  Nat Protoc       Date:  2017-12-14       Impact factor: 13.491

Review 7.  Expression vector cassette engineering for recombinant therapeutic production in mammalian cell systems.

Authors:  Tian-Yun Wang; Xiao Guo
Journal:  Appl Microbiol Biotechnol       Date:  2020-05-06       Impact factor: 4.813

8.  Heterologous protein production using euchromatin-containing expression vectors in mammalian cells.

Authors:  Katalin Zboray; Wolfgang Sommeregger; Edith Bogner; Andreas Gili; Thomas Sterovsky; Katharina Fauland; Beatrice Grabner; Patricia Stiedl; Herwig P Moll; Anton Bauer; Renate Kunert; Emilio Casanova
Journal:  Nucleic Acids Res       Date:  2015-05-14       Impact factor: 16.971

9.  Production of functional soluble Dectin-1 glycoprotein using an IRES-linked destabilized-dihydrofolate reductase expression vector.

Authors:  Say Kong Ng; Tessa Rui Min Tan; Yang Wang; Daniel Ng; Lin-Tang Goh; Muriel Bardor; Victor Vai Tak Wong; Kong Peng Lam
Journal:  PLoS One       Date:  2012-12-26       Impact factor: 3.240

10.  Advances in Mammalian cell line development technologies for recombinant protein production.

Authors:  Tingfeng Lai; Yuansheng Yang; Say Kong Ng
Journal:  Pharmaceuticals (Basel)       Date:  2013-04-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.